ATM and breast cancer: estimated an OR of 1.8 (95% CI 1.46–2.27, p < 0.001) and, by combining this OR with the SEER breast cancer incidence rates for the population, derived an estimate of lifetime absolute risk of breast cancer greater than 20% for ATM pathogenic variant carriers.